FUB-PB-22

FUB-PB-22, also known as QCBL-Bz-F or MN-27, is a synthetic cannabinoid in the quinolinyl ester indole family. It contains a 4-fluorobenzyl substituent on the indole nitrogen and a quinolin-8-yl ester group. It was identified in herbal blends in 2014 and has been examined in human metabolism studies, but its receptor pharmacology and clinical effects are not well characterised.

Chemistry and identification

FUB-PB-22 is quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate. It is the quinoline counterpart of FDU-PB-22, which contains a naphthalene ester group. It is also structurally distinct from 5F-PB-22, which carries a 5-fluoropentyl chain rather than a 4-fluorobenzyl group.

The compound was detected in herbal blends in Japan, Russia and Germany in 2014. UNODC’s forensic identification manual lists its full chemical structure and analytical reference information (UNODC recommended methods for synthetic cannabinoid analysis).

Pharmacology

FUB-PB-22 is classified as a synthetic cannabinoid receptor agonist. However, the 2016 human metabolism study noted that controlled pharmacological and toxicological data were not available at the time. Its structural similarity to PB-22 and other indole ester cannabinoids provides context, but does not establish a specific CB₁ or CB₂ potency value (Diao and colleagues, 2016).

Metabolism and forensic detection

FUB-PB-22 was rapidly metabolised in human liver microsomes, with an estimated in-vitro half-life of 11.5 minutes. Seven metabolites were identified in hepatocyte incubations. Ester hydrolysis produced a fluorobenzylindole-3-carboxylic acid metabolite, followed by hydroxylation and glucuronidation. The same major metabolites were detected in an authentic urine specimen from a confirmed case (Diao and colleagues, 2016).

Because FUB-PB-22 and FDU-PB-22 share the fluorobenzylindole portion of their structures, ester hydrolysis leads to the same principal fluorobenzylindole carboxylic acid marker. Additional metabolites can help distinguish the compounds, but the shared marker alone is not necessarily sufficient to identify which parent substance was present.

Reported effects and clinical evidence

The 2016 study confirmed exposure in authentic urine, but did not provide a clinical symptom profile. The authors noted that online user reports were unreliable because individuals often did not know the actual composition of the products they had consumed. There is therefore not enough evidence to describe a characteristic FUB-PB-22 experience.

Toxicity and research limitations

The acute toxic range, dependence potential and long-term effects of FUB-PB-22 have not been established in a detailed clinical case series. The main published evidence concerns chemical identification and metabolism. Its classification as a synthetic cannabinoid does not by itself show how strongly it acts at receptors or how severe its effects are in humans.

Related compounds

FUB-PB-22 is related to FDU-PB-22, PB-22 and 5F-PB-22. Its 4-fluorobenzyl group and quinolinyl ester distinguish it from the fluoropentyl analogue 5F-PB-22.